Real-world prognostic value of RET fusions in advanced non-small cell lung cancer (aNSCLC)

被引：0

作者：

Gadgeel, S. M. ^{[1
]}

Zhang, Q. ^{[2
]}

Lin, H. ^{[3
]}

Fajardo, O. ^{[4
]}

Trinh, H. ^{[5
]}

Arndorfer, S. ^{[6
]}

Kong, S. ^{[7
]}

Rahman, A. ^{[8
]}

Li, S. ^{[9
]}

Archer, V. R. ^{[10
]}

Gainor, J. F. ^{[11
]}

机构：

[1] Henry Ford Hlth Syst, Dept Internal Med, Henry Ford Canc Inst, Detroit, MI USA

[2] Genentech Inc, Product Dev Data Sci, San Francisco, CA USA

[3] Roche Holding Ltd, Roche Product Dev Shanghai, Shanghai, CA, Peoples R China

[4] F Hoffmann La Roche Ltd, Product Dev Data Sci, Basel, Switzerland

[5] Genentech Inc, Product Dev Real World Data Sci, San Francisco, CA USA

[6] Genesis Res, Real World Evidence, Hoboken, NJ USA

[7] Genentech Inc, Biostat, San Francisco, CA USA

[8] Roche Prod Ltd, Product Dev Clin Dev, Welwyn Garden City, Herts, England

[9] Genentech Inc, Product Dev Oncol, San Francisco, CA USA

[10] Roche Prod Ltd, PDC, Welwyn Garden City, Herts, England

[11] Massachusetts Gen Hosp, Ctr Thorac Cancers, Dept Med, Canc Ctr, Boston, MA USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2421

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1388P

引用

页数：2

共 50 条

[21] Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer
Long, Chaolian
Li, Kun
Liu, Zichen
Zhang, Nana
Xing, Xuya
Xu, Liming
Gai, Fei
Che, Nanying
[J]. CANCER MEDICINE, 2023, 12 (07): : 7982 - 7991
[22] COMPARISON OF REAL-WORLD OUTCOMES BETWEEN A CLINICAL-GENOMICS DATABASE AND OTHER REAL-WORLD DATABASES AMONG IMMUNOTHERAPYTREATED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)
Liao, J.
Zhang, N.
Das, A.
[J]. VALUE IN HEALTH, 2024, 27 (06) : S367 - S367
[23] The Real-World Efficacy and Safety of Anlotinib Treatment for Advanced Non-Small Cell Lung Cancer
Wang, F.
Jin, F.
Wang, S.
Zhu, Y.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S673 - S673
[24] Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
Zhang, Kun
Ma, Xiya
Gao, Hongjun
Wang, Hong
Qin, Haifeng
Yang, Shaoxing
Liu, Xiaoqing
[J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3409 - 3417
[25] A Real-World Study: Efficacy and Safety of Anlotinib for Advanced Non-Small Cell Lung Cancer
Wang, J.
Yi, T.
Dong, Y.
Ran, R.
Cao, F.
Li, Y.
Luo, Z.
Xu, Y.
Fu, Y.
Kuang, L.
Chen, G.
Qu, G.
Yin, Y.
Li, J.
Xu, X.
Chen, Y.
Song, Q.
Chu, Q.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1071 - S1071
[26] COST OF CARE IN ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) IN THE IMMUNO-ONCOLOGY (10) ERA: A REAL-WORLD ANALYSIS OF EARLY DATA
Radtchenko, J.
Korytowsky, B.
Nwokeji, E.
Tuell, K.
Feinberg, B.
[J]. VALUE IN HEALTH, 2018, 21 : S122 - S123
[27] Real-world survival with first-line (1L) chemotherapy in patients (pts) with advanced non-small cell lung cancer (aNSCLC)
Waterhouse, D.
Betts, K. A.
Zhao, J.
Rao, S.
Gupte-Singh, K.
Rutstein, M.
Higashi, M. K.
Schwartzberg, L.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 29 - U99
[28] Real-world data analysis of PD-L1 expression and overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Staib, J.
Sudarsanam, S.
Byfield, S. Dacosta
Kennedy, C.
Weiss, L.
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 27 - 27
[29] Real-World (RW) Predictors of Immuno-Oncology (IO) vs Chemotherapy (C) Use in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Radtchenko, J.
Korytowsky, B.
Nwokeji, E.
Tue, K.
Feinberg, B.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S889 - S889
[30] Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).
Khozin, Sean
Walker, Mark S.
Jun, Monika
Chen, Li
Stepanski, Edward
Rubinstein, Wendy S.
Komatsoulis, George Anthony
Roberts, Jeremy
Zhi, Jizu
Miller, Robert S.
Fukushima, Ryan
Lau, Denise
Hyde, Brigham
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →